Celltech Group PLC (CLL) Outlines Positive Preliminary Results From First CDP870 Phase III Trial In Rheumatoid Arthritis
10/19/2005 5:10:38 PM
Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces positive preliminary results from the first Phase III clinical trial with CDP870 in rheumatoid arthritis ("Study 014"). Study 014 was designed to assess the safety and efficacy of CDP870 in combination with methotrexate on signs and symptoms of disease over a six month period in a refractory group of patients, who had active moderate to severe disease despite treatment with methotrexate and other disease modifying anti-rheumatic drugs ("DMARDs").
comments powered by